CSF3, colony stimulating factor 3, 1440

N. diseases: 687; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 Biomarker disease BEFREE Further studies on the roles of CCL11, CXCL10, and G-CSF may be especially important in terms of potential prevention of SAE between 4 and 24 h after the onset of sepsis. 31628962 2020
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 Biomarker disease BEFREE Neutrophils from older adults appear to be dysfunctional, displaying a reduced ability to target infected or inflamed tissue, poor phagocytic responses and a reduced capacity to release neutrophil extracellular traps (NETs); this occurs in health, but responses are further diminished during infection and particularly during sepsis, where a reduced response to granulocyte colony-stimulating factor (G-CSF) inhibits the release of immature neutrophils from the bone marrow. 31732687 2020
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 GeneticVariation disease BEFREE The most common serious adverse events were ascites (two patients in the G-CSF group and two patients in the G-CSF plus stem-cell infusion group, one of whom was admitted to hospital with ascites twice), sepsis (four patients in the G-CSF plus stem-cell infusion group), and encephalopathy (three patients in the G-CSF plus stem-cell infusion group, one of whom was admitted to hospital with encephalopathy twice). 29127060 2018
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 AlteredExpression disease BEFREE Filgrastim upregulates expression of these markers, and we observed deficiency in the IL-23-IL-17 axis accompanying sepsis. 28769538 2017
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 GeneticVariation disease BEFREE <b>Objective</b> The objective of this study was to determine the time to hematologic recovery and the incidence of secondary sepsis and mortality among neutropenic infants treated or not treated with granulocyte colony-stimulating factor (G-CSF). 27649291 2017
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 AlteredExpression disease BEFREE In an animal model of sepsis, EGCG significantly elevated peritoneal levels of G-CSF and several chemokines (e.g., MCP-1/CCL2 and MIP-1γ/CCL9), and consequently increased peritoneal neutrophil numbers (neutrophilia) at a late stage. 26293782 2015
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 GeneticVariation disease BEFREE Deaths were mainly due to sepsis (5 patients, 4/5 not responding to G-CSF, none with G6PC3 mutation). 25284454 2015
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 Biomarker disease BEFREE This review will briefly summarize the role of neutrophils and the therapeutic effect of G-CSF in sepsis. 26798659 2015
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 AlteredExpression disease BEFREE Transfer of a normal microbiota into antibiotic-treated neonates induced IL-17 production by group 3 innate lymphoid cells (ILCs) in the intestine, increasing plasma G-CSF levels and neutrophil numbers in a Toll-like receptor 4 (TLR4)- and myeloid differentiation factor 88 (MyD88)-dependent manner and restored IL-17-dependent resistance to sepsis. 24747744 2014
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 Biomarker disease BEFREE G-CSF administration as an adjuvant therapy for neonatal septicemia, whether neutropenic or not, improves neutrophilic count and function and contributed to early healing from sepsis. 22475305 2012
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 GeneticVariation disease BEFREE The treatment of children affected by severe congenital neutropenia (SCN) with G-CSF strongly reduces the risk of sepsis by reversing neutropenia. 17311988 2007
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 Therapeutic disease CTD_human In those patients who survive the initial phase of poisoning, filgrastim (granulocyte colony-stimulating factor) offers an effective method of treating pancytopenia and preventing overwhelming septicemia. 17505274 2007
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 Biomarker disease BEFREE These 14 markers, as well as the previously described PRV1 and NF-E2, exhibited the same gene expression alterations also in patients with exogenously activated granulocytes due to sepsis or granulocyte colony-stimulating factor (G-CSF) treatment. 16081684 2005
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 Biomarker disease BEFREE He eventually developed resistance to G-CSF and died from sepsis after cytotoxic therapy. 15203865 2004
CUI: C0036690
Disease: Septicemia
Septicemia
0.400 Biomarker disease BEFREE The propositus was unresponsive to G-CSF and eventually died of sepsis. 10815788 2000